Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

August 04, 2016

AbbVie Inc. et al v. Amgen Inc. et al

Track this case

Case Number:

1:16-cv-00666

Court:

Delaware

Nature of Suit:

Patent

Judge:

Mitchell S. Goldberg

Firms

Companies

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. September 28, 2017

    AbbVie, Amgen End Patent Fight Over Humira Biosimilar

    AbbVie Inc. and Amgen Inc. on Thursday announced a patent litigation settlement that will keep a biosimilar version of Humira, the world's best-selling drug, out of European pharmacies until 2018 and U.S. pharmacies until 2023.

1 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login